Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bryan Rainbolt

Physician Assistant Suwanee, GA Physician Assistant

NPI 1013577873 CMS profile 11304776

1300 Peachtree Industrial Blvd Ste 4101, Suwanee, GA 30024

Open in the dashboard

General payments

$4,216

143 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bryan Rainbolt of Suwanee, GA is reported in the CMS Open Payments database as having received $4,216 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,211 142
2021 General $5 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bryan Rainbolt
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Bryan Rainbolt were reported at $4,211. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Bryan Rainbolt Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $5 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $0 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $4,211 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $785 13 payments
  2. Genzyme Corporation $624 16 payments
  3. AbbVie, Inc. $427 14 payments
  4. UCB, Inc. $363 20 payments
  5. Janssen Biotech, Inc. $277 6 payments
  6. Arcutis Biotherapeutics, Inc. $229 15 payments
  7. Sun Pharmaceutical Industries Inc. $210 11 payments
  8. LEO Pharma Inc. $196 7 payments
  9. Galderma Laboratories, L.P. $185 7 payments
  10. Novartis Pharmaceuticals Corporation $181 7 payments
  11. Other $741 27 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,026 141 payments
  2. Education $190 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology And Inflammation $785 13 payments
  2. DUPIXENT Immunology $714 17 payments
  3. SKYRIZI $359 11 payments
  4. TREMFYA $277 6 payments
  5. Bimzelx $273 18 payments
  6. Zoryve $229 15 payments
  7. RINVOQ $189 4 payments
  8. NEMLUVIO $185 7 payments
  9. Xeomin $150 1 payment
  10. ADBRY $136 4 payments
  11. Other $894 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

484

Median for Physician Assistant: 241

Drug cost

$3,993

Median for Physician Assistant: $4,110

Branded share of claims

27.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 64 $1,391
Albuterol Sulfate Hfa Albuterol Sulfate Brand 28 $580
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 69 $573
Azithromycin Generic 144 $561
Doxycycline Hyclate Generic 37 $316
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 24 $292
Prednisone Generic 69 $97
Ciprofloxacin Hcl Generic 15 $67
Cephalexin Generic 11 $55
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $44

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$20,983

Of which drugs: $303

Medicare patients

264

Average age 74

Services billed

1,816

166 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 50%
Ischemic heart disease 28%
Osteoporosis 22%
Depression 21%
Diabetes 18%
Chronic kidney disease 18%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 104 1,026 $80
Injection, ceftriaxone sodium, per 250 mg J0696 Office 27 112 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record